{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T07:15:04Z","timestamp":1789456504601,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T00:00:00Z","timestamp":1786752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T00:00:00Z","timestamp":1786752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Defese Medical Product"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00228-026-04166-9","type":"journal-article","created":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T04:56:42Z","timestamp":1786769802000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Investigating PXR (NR1I2) genetic polymorphisms as possible determinants of the magnitude of the clindamycin\u2013rifampicin pharmacokinetic interaction"],"prefix":"10.1007","volume":"82","author":[{"given":"Val\u00e9rie","family":"Zeller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelle","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9o","family":"Mimram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamilia","family":"Brinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Younes","family":"Kerroumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armelle","family":"Arnoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Anne","family":"Loriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Narjoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Jullien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,15]]},"reference":[{"key":"4166_CR1","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1128\/AAC.46.3.900-903.2002","volume":"46","author":"Z Zheng","year":"2002","unstructured":"Zheng Z, Stewart PS (2002) Penetration of rifampin through Staphylococcus epidermidis biofilms. Antimicrob Agents Chemother 46:900\u2013903. https:\/\/doi.org\/10.1128\/AAC.46.3.900-903.2002","journal-title":"Antimicrob Agents Chemother"},{"key":"4166_CR2","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ijantimicag.2008.08.029","volume":"33","author":"K Smith","year":"2009","unstructured":"Smith K, Perez A, Ramage G et al (2009) Comparison of biofilm-associated cell survival following in vitro exposure of meticillin-resistant Staphylococcus aureus biofilms to the antibiotics clindamycin, daptomycin, linezolid, tigecycline and vancomycin. Int J Antimicrob Agents 33:374\u2013378. https:\/\/doi.org\/10.1016\/j.ijantimicag.2008.08.029","journal-title":"Int J Antimicrob Agents"},{"key":"4166_CR3","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2165\/00003088-200948020-00002","volume":"48","author":"CB Landersdorfer","year":"2009","unstructured":"Landersdorfer CB, Bulitta JB, Kinzig M et al (2009) Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations. Clin Pharmacokinet 48:89\u2013124","journal-title":"Clin Pharmacokinet"},{"key":"4166_CR4","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1128\/AAC.33.2.245","volume":"33","author":"M Arditi","year":"1989","unstructured":"Arditi M, Yogev R (1989) In vitro interaction between rifampin and clindamycin against pathogenic coagulase-negative staphylococci. Antimicrob Agents Chemother 33:245\u2013247. https:\/\/doi.org\/10.1128\/AAC.33.2.245","journal-title":"Antimicrob Agents Chemother"},{"key":"4166_CR5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/0732-8893(86)90147-1","volume":"4","author":"JL Ho","year":"1986","unstructured":"Ho JL, Klempner MS (1986) In vitro evaluation of clindamycin in combination with oxacillin, rifampin, or vancomycin against Staphylococcus aureus. Diagn Microbiol Infect Dis 4:133\u2013138. https:\/\/doi.org\/10.1016\/0732-8893(86)90147-1","journal-title":"Diagn Microbiol Infect Dis"},{"key":"4166_CR6","doi-asserted-by":"publisher","first-page":"962","DOI":"10.3109\/00365548.2011.608082","volume":"43","author":"J Czekaj","year":"2011","unstructured":"Czekaj J, Dinh A, Moldovan A et al (2011) Efficacy of a combined oral clindamycin?rifampicin regimen for therapy of staphylococcal osteoarticular infections. Scand J Infect Dis 43:962\u2013967. https:\/\/doi.org\/10.3109\/00365548.2011.608082","journal-title":"Scand J Infect Dis"},{"key":"4166_CR7","doi-asserted-by":"publisher","first-page":"819","DOI":"10.2165\/00003088-200342090-00003","volume":"42","author":"M Niemi","year":"2003","unstructured":"Niemi M, Backman JT, Fromm MF et al (2003) Pharmacokinetic interactions with rifampicin : clinical relevance. Clin Pharmacokinet 42:819\u2013850. https:\/\/doi.org\/10.2165\/00003088-200342090-00003","journal-title":"Clin Pharmacokinet"},{"key":"4166_CR8","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1124\/dmd.31.7.878","volume":"31","author":"MA Wynalda","year":"2003","unstructured":"Wynalda MA, Hutzler JM, Koets MD et al (2003) In vitro metabolism of clindamycin in human liver and intestinal microsomes. Drug Metab Dispos 31:878\u2013887. https:\/\/doi.org\/10.1124\/dmd.31.7.878","journal-title":"Drug Metab Dispos"},{"key":"4166_CR9","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/j.1445-5994.1975.tb04568.x","volume":"5","author":"BA Peddie","year":"1975","unstructured":"Peddie BA, Dann E, Bailey RR (1975) The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin. Aust N Z J Med 5:198\u2013202. https:\/\/doi.org\/10.1111\/j.1445-5994.1975.tb04568.x","journal-title":"Aust N Z J Med"},{"key":"4166_CR10","doi-asserted-by":"publisher","unstructured":"Zeller V, Magreault S, Heym B et al (2021) Influence of the clindamycin administration route on the magnitude of clindamycin-rifampicin interaction: a prospective pharmacokinetic study. Clin Microbiol Infect 27:857.https:\/\/doi.org\/10.1016\/j.cmi.2021.04.017","DOI":"10.1016\/j.cmi.2021.04.017"},{"key":"4166_CR11","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.cmi.2025.01.005","volume":"31","author":"S Magr\u00e9ault","year":"2025","unstructured":"Magr\u00e9ault S, Berrah R, Kerroumi Y et al (2025) Dosing and route of administration of clindamycin given in combination with rifampicin. Clin Microbiol Infect 31:832\u2013838. https:\/\/doi.org\/10.1016\/j.cmi.2025.01.005","journal-title":"Clin Microbiol Infect"},{"key":"4166_CR12","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1128\/AAC.01081-09","volume":"54","author":"V Zeller","year":"2010","unstructured":"Zeller V, Dzeing-Ella A, Kitzis M-D et al (2010) Continuous clindamycin infusion, an innovative approach to treating bone and joint infections. Antimicrob Agents Chemother 54:88\u201392. https:\/\/doi.org\/10.1128\/AAC.01081-09","journal-title":"Antimicrob Agents Chemother"},{"key":"4166_CR13","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.2217\/14622416.9.11.1695","volume":"9","author":"B Zhang","year":"2008","unstructured":"Zhang B, Xie W, Krasowski MD (2008) PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics 9:1695\u20131709. https:\/\/doi.org\/10.2217\/14622416.9.11.1695","journal-title":"Pharmacogenomics"},{"key":"4166_CR14","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1097\/00008571-200110000-00003","volume":"11","author":"J Zhang","year":"2001","unstructured":"Zhang J, Kuehl P, Green ED et al (2001) The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 11:555\u2013572. https:\/\/doi.org\/10.1097\/00008571-200110000-00003","journal-title":"Pharmacogenetics"},{"key":"4166_CR15","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1093\/ndt\/gfy096","volume":"33","author":"F Stifft","year":"2018","unstructured":"Stifft F, van Kuijk SMJ, Bekers O, Christiaans MHL (2018) Increase in tacrolimus exposure after steroid tapering is influenced by CYP3A5 and pregnane X receptor genetic polymorphisms in renal transplant recipients. Nephrol Dialysis Transplantation 33:1668\u20131675. https:\/\/doi.org\/10.1093\/ndt\/gfy096","journal-title":"Nephrol Dialysis Transplantation"},{"key":"4166_CR16","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1080\/00498254.2021.1928791","volume":"51","author":"L Wang","year":"2021","unstructured":"Wang L, Zeng G, Li J et al (2021) Association of polymorphism of CYP3A4, ABCB1, ABCC2, ABCG2, NFKB1, POR, and PXR with the concentration of cyclosporin A in allogeneic haematopoietic stem cell transplantation recipients. Xenobiotica 51:852\u2013858. https:\/\/doi.org\/10.1080\/00498254.2021.1928791","journal-title":"Xenobiotica"},{"key":"4166_CR17","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1007\/s40262-025-01533-0","volume":"64","author":"MI Francke","year":"2025","unstructured":"Francke MI, Sassen SDT, Lloberas N et al (2025) A Population Pharmacokinetic Model and Dosing Algorithm to Guide the Tacrolimus Starting and Follow-Up Dose in Living and Deceased Donor Kidney Transplant Recipients. Clin Pharmacokinet 64:1379\u20131394. https:\/\/doi.org\/10.1007\/s40262-025-01533-0","journal-title":"Clin Pharmacokinet"},{"key":"4166_CR18","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jad.2024.10.112","volume":"370","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Hao Y, Wang Z et al (2025) Effect of CYP3A5*3 genotype on exposure and efficacy of quetiapine: A retrospective, cohort study. J Affect Disord 370:134\u2013139. https:\/\/doi.org\/10.1016\/j.jad.2024.10.112","journal-title":"J Affect Disord"},{"key":"4166_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1096\/fasebj.2020.34.s1.02015","volume":"34","author":"A Kapetas","year":"2020","unstructured":"Kapetas A (2020) A Clinical Study To Assess The Magnitude, Time-course And Variability Of CYP3A4 Induction By Rifampin In Healthy Volunteers. FASEB J 34:1\u20131. https:\/\/doi.org\/10.1096\/fasebj.2020.34.s1.02015","journal-title":"FASEB J"},{"key":"4166_CR20","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1208\/s12248-019-0341-y","volume":"21","author":"AJ Kapetas","year":"2019","unstructured":"Kapetas AJ, Sorich MJ, Rodrigues AD, Rowland A (2019) Guidance for Rifampin and Midazolam Dosing Protocols To Study Intestinal and Hepatic Cytochrome P450 (CYP) 3A4 Induction and De-induction. AAPS J 21:78. https:\/\/doi.org\/10.1208\/s12248-019-0341-y","journal-title":"AAPS J"},{"key":"4166_CR21","doi-asserted-by":"publisher","first-page":"778","DOI":"10.2174\/138920007782798199","volume":"8","author":"X-D Wang","year":"2007","unstructured":"Wang X-D, Li J-L, Su Q-B et al (2007) A pharmacogenetic study of pregnane X receptor (NR1I2) in Han Chinese. Curr Drug Metab 8:778\u2013786. https:\/\/doi.org\/10.2174\/138920007782798199","journal-title":"Curr Drug Metab"},{"key":"4166_CR22","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/j.1600-0765.2011.01417.x","volume":"47","author":"M Folwaczny","year":"2012","unstructured":"Folwaczny M, Tengler B, Glas J (2012) Variants of the human NR1I2 (PXR) locus in chronic periodontitis. J Periodontal Res 47:174\u2013179. https:\/\/doi.org\/10.1111\/j.1600-0765.2011.01417.x","journal-title":"J Periodontal Res"},{"key":"4166_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2217\/pgs-2017-0121","volume":"19","author":"LC Mbatchi","year":"2018","unstructured":"Mbatchi LC, Brouillet J-P, Evrard A (2018) Genetic variations of the xenoreceptors NR1I2 and NR1I3 and their effect on drug disposition and response variability. Pharmacogenomics 19:61\u201377. https:\/\/doi.org\/10.2217\/pgs-2017-0121","journal-title":"Pharmacogenomics"},{"key":"4166_CR24","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1097\/FTD.0000000000001237","volume":"46","author":"S Magreault","year":"2024","unstructured":"Magreault S, Pierredon D, Akinotcho-Relouzat J et al (2024) From Bed to Bench: Pre-analytical Stability of 29 Anti-infective Agents in Plasma and Whole Blood to Improve Accuracy of Therapeutic Drug Monitoring. Ther Drug Monit 46:725\u2013734. https:\/\/doi.org\/10.1097\/FTD.0000000000001237","journal-title":"Ther Drug Monit"},{"key":"4166_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1185\/03007995.2012.747952","volume":"29","author":"AM Baciewicz","year":"2013","unstructured":"Baciewicz AM, Chrisman CR, Finch CK, Self TH (2013) Update on rifampin, rifabutin, and rifapentine drug interactions. Curr Med Res Opin 29:1\u201312. https:\/\/doi.org\/10.1185\/03007995.2012.747952","journal-title":"Curr Med Res Opin"},{"key":"4166_CR26","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/phar.2672","volume":"42","author":"C MacDougall","year":"2022","unstructured":"MacDougall C, Canonica T, Keh C et al (2022) Systematic review of drug-drug interactions between rifamycins and anticoagulant and antiplatelet agents and considerations for management. Pharmacotherapy 42:343\u2013361. https:\/\/doi.org\/10.1002\/phar.2672","journal-title":"Pharmacotherapy"},{"key":"4166_CR27","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jinf.2015.03.013","volume":"71","author":"A Bernard","year":"2015","unstructured":"Bernard A, Kermarrec G, Parize P et al (2015) Dramatic reduction of clindamycin serum concentration in staphylococcal osteoarticular infection patients treated with the oral clindamycin-rifampicin combination. J Infect 71:200\u2013206. https:\/\/doi.org\/10.1016\/j.jinf.2015.03.013","journal-title":"J Infect"},{"key":"4166_CR28","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s15010-015-0773-y","volume":"43","author":"E Curis","year":"2015","unstructured":"Curis E, Pestre V, Jullien V et al (2015) Pharmacokinetic variability of clindamycin and influence of rifampicin on clindamycin concentration in patients with bone and joint infections. Infection 43:473\u2013481. https:\/\/doi.org\/10.1007\/s15010-015-0773-y","journal-title":"Infection"},{"key":"4166_CR29","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1684\/ejd.2013.2213","volume":"24","author":"O Join-Lambert","year":"2014","unstructured":"Join-Lambert O, Ribadeau-Dumas F, Jullien V et al (2014) Dramatic reduction of clindamycin plasma concentration in hidradenitis suppurativa patients treated with the rifampin-clindamycin combination. Eur J Dermatol 24:94\u201395. https:\/\/doi.org\/10.1684\/ejd.2013.2213","journal-title":"Eur J Dermatol"},{"key":"4166_CR30","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/01.fpc.0000215070.52212.0e","volume":"16","author":"M Niemi","year":"2006","unstructured":"Niemi M, Kivist\u00f6 KT, Diczfalusy U et al (2006) Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin. Pharmacogenet Genomics 16:565\u2013568. https:\/\/doi.org\/10.1097\/01.fpc.0000215070.52212.0e","journal-title":"Pharmacogenet Genomics"},{"key":"4166_CR31","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.2147\/DDDT.S495647","volume":"19","author":"H Xie","year":"2025","unstructured":"Xie H, Zheng Y, Zhang H et al (2025) Association of NR1I2 Polymorphism with Midazolam Clearance in Mechanically Ventilated ICU Patients: A Population Pharmacokinetic and Pharmacogenetic Study. Drug Des Devel Ther 19:1527\u20131541. https:\/\/doi.org\/10.2147\/DDDT.S495647","journal-title":"Drug Des Devel Ther"},{"key":"4166_CR32","doi-asserted-by":"publisher","first-page":"5242","DOI":"10.1128\/AAC.00781-10","volume":"54","author":"A Schipani","year":"2010","unstructured":"Schipani A, Siccardi M, D\u2019Avolio A et al (2010) Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance. Antimicrob Agents Chemother 54:5242\u20135250. https:\/\/doi.org\/10.1128\/AAC.00781-10","journal-title":"Antimicrob Agents Chemother"},{"key":"4166_CR33","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1097\/QAI.0b013e3181f52f0c","volume":"55","author":"J Sv\u00e4rd","year":"2010","unstructured":"Sv\u00e4rd J, Spiers JP, Mulcahy F, Hennessy M (2010) Nuclear receptor-mediated induction of CYP450 by antiretrovirals: functional consequences of NR1I2 (PXR) polymorphisms and differential prevalence in whites and sub-Saharan Africans. J Acquir Immune Defic Syndr 55:536\u2013549. https:\/\/doi.org\/10.1097\/QAI.0b013e3181f52f0c","journal-title":"J Acquir Immune Defic Syndr"},{"key":"4166_CR34","doi-asserted-by":"publisher","first-page":"232","DOI":"10.2174\/1389200221999210104204057","volume":"22","author":"R Meng","year":"2021","unstructured":"Meng R, Zhang X, Wang H et al (2021) Different Inductive Effects of Praziquantel Racemate and its Enantiomers on the Enzyme CYP3A4 Mediated by Pregnane X Receptor and its Variants. Curr Drug Metab 22:232\u2013239. https:\/\/doi.org\/10.2174\/1389200221999210104204057","journal-title":"Curr Drug Metab"},{"key":"4166_CR35","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1124\/dmd.110.035246","volume":"39","author":"JY Chung","year":"2011","unstructured":"Chung JY, Cho J-Y, Lim H-S et al (2011) Effects of pregnane X receptor (NR1I2) and CYP2B6 genetic polymorphisms on the induction of bupropion hydroxylation by rifampin. Drug Metab Dispos 39:92\u201397. https:\/\/doi.org\/10.1124\/dmd.110.035246","journal-title":"Drug Metab Dispos"},{"key":"4166_CR36","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.bcp.2013.05.016","volume":"86","author":"K Watanabe","year":"2013","unstructured":"Watanabe K, Sakurai K, Tsuchiya Y et al (2013) Dual roles of nuclear receptor liver X receptor \u03b1 (LXR\u03b1) in the CYP3A4 expression in human hepatocytes as a positive and negative regulator. Biochem Pharmacol 86:428\u2013436. https:\/\/doi.org\/10.1016\/j.bcp.2013.05.016","journal-title":"Biochem Pharmacol"},{"key":"4166_CR37","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3748\/wjg.v17.i2.197","volume":"17","author":"V Andersen","year":"2011","unstructured":"Andersen V, Christensen J, Ernst A et al (2011) Polymorphisms in NF-\u03baB, PXR, LXR, PPAR\u03b3 and risk of inflammatory bowel disease. World J Gastroenterol 17:197\u2013206. https:\/\/doi.org\/10.3748\/wjg.v17.i2.197","journal-title":"World J Gastroenterol"},{"key":"4166_CR38","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1006\/bbrc.2000.3219","volume":"274","author":"JM Pascussi","year":"2000","unstructured":"Pascussi JM, Gerbal-Chaloin S, Pichard-Garcia L et al (2000) Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes. Biochem Biophys Res Commun 274:707\u2013713. https:\/\/doi.org\/10.1006\/bbrc.2000.3219","journal-title":"Biochem Biophys Res Commun"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04166-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04166-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04166-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:47:29Z","timestamp":1789454849000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04166-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,15]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["4166"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04166-9","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,15]]},"assertion":[{"value":"1 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no conflicts of interest.","order":2,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"234"}}